[go: up one dir, main page]

PE115699A1 - PROTEASE CO-INHIBITORS - Google Patents

PROTEASE CO-INHIBITORS

Info

Publication number
PE115699A1
PE115699A1 PE1998000830A PE00083098A PE115699A1 PE 115699 A1 PE115699 A1 PE 115699A1 PE 1998000830 A PE1998000830 A PE 1998000830A PE 00083098 A PE00083098 A PE 00083098A PE 115699 A1 PE115699 A1 PE 115699A1
Authority
PE
Peru
Prior art keywords
alkyl
protease
ch2cf3
compound
treat
Prior art date
Application number
PE1998000830A
Other languages
Spanish (es)
Inventor
Renee Louise Desjarlais
Iv Sigfried Benjamin Christensen
Cornelia Jutta Forster
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE115699A1 publication Critical patent/PE115699A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X, X1, X2 Y X3 SON H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON F, CICLOALQUILO C3-C7, CN, C(O)R1, C(NCN)SR3, O(CH2)qC(O)NR1R2, S(O)mR3, ENTRE OTROS; m ES 0-2; q ES 1-2; n ES 0-2; R1 ES H, ALQUILO C1-C6, CF3, CH2CF3; O R1 Y R2 JUNTO CON N FORMAN UN ANILLO DE 5-7 MIEMBROS; R2 ES H, ALQUILO C1-C6, CF3, CH2CF3; R3 ES ALQUILO C1-C6, CF3, CH2CF3 Y X4 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, COAr, COO-ALQUILO C1-C6, COOAr. UN COMPUESTO PREFERIDO ES N-BENCIL-N`-{4-{3-[4-(N-METIL-N-FENIL)AMINO-BUTOXI]-FENIL}TIAZOL-2-IL}GUANIDINA, ENTRE OTROS. EL COMPUESTO I INHIBE A UNA PROTEASA, DE PREFERENCIA A UNA CISTEINA-PROTEASA O UNA SERINA-PROTEASA; POR LO QUE PUEDE SER UTIL PARA TRATAR UNA ENFERMEDAD CARACTERIZADA POR PERDIDA DE HUESO COMO OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS O TRATAR UNA ENFERMEDAD CARACTERIZADA POR LA EXCESIVA DEGRADACION DEL CARTILAGO DE LA MATRIZ COMO OSTEOARTRITIS, ARTRITIS REUMATOIDEREFERS TO A COMPOUND OF FORMULA I, WHERE X, X1, X2 AND X3 ARE H, ALKYL C1-C6 OPTIONALLY REPLACED WITH F, CYCLLOALKYL C3-C7, CN, C (O) R1, C (NCN) SR3, O ( CH2) qC (O) NR1R2, S (O) mR3, AMONG OTHERS; m IS 0-2; q IS 1-2; n ES 0-2; R1 IS H, C1-C6-ALKYL, CF3, CH2CF3; OR R1 AND R2 TOGETHER WITH N FORM A RING OF 5-7 MEMBERS; R2 IS H, C1-C6-ALKYL, CF3, CH2CF3; R3 IS C1-C6 ALKYL, CF3, CH2CF3 AND X4 IS H, C1-C6 ALKYL, CYCLOALKYL C3-C7, COAr, COO-C1-C6 ALKYL, COOAr. A PREFERRED COMPOUND IS N-BENCIL-N`- {4- {3- [4- (N-METHYL-N-PHENYL) AMINO-BUTOXI] -FENYL} THIAZOL-2-IL} GUANIDINE, AMONG OTHERS. COMPOUND I INHIBITS A PROTEASE, PREFERRED TO A CYSTEINE-PROTEASE OR SERINE-PROTEASE; SO IT MAY BE USEFUL TO TREAT A DISEASE CHARACTERIZED BY LOSS OF BONE LIKE OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS OR TREAT A DISEASE CHARACTERIZED BY THE EXCESSIVE DEGRADATION OF THE CARTILAGE OF THE MATRIX, OSTEOARTRITIS,

PE1998000830A 1997-09-04 1998-09-04 PROTEASE CO-INHIBITORS PE115699A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5752797P 1997-09-04 1997-09-04

Publications (1)

Publication Number Publication Date
PE115699A1 true PE115699A1 (en) 2000-01-13

Family

ID=22011125

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000830A PE115699A1 (en) 1997-09-04 1998-09-04 PROTEASE CO-INHIBITORS

Country Status (10)

Country Link
EP (1) EP1015438A4 (en)
JP (1) JP2001514257A (en)
AU (1) AU9300298A (en)
CA (1) CA2302361A1 (en)
CO (1) CO4970736A1 (en)
MA (1) MA26540A1 (en)
PE (1) PE115699A1 (en)
SA (1) SA98190653A (en)
WO (1) WO1999011637A1 (en)
ZA (1) ZA988064B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
NZ520588A (en) 2000-03-21 2004-06-25 Smithkline Beecham Corp Protease inhibitors
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
KR100962972B1 (en) 2002-07-26 2010-06-09 주식회사유한양행 1-phenylpiperidin-3-one derivatives and preparation method thereof
DE102004008141A1 (en) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidine compounds and their use as binding partners for 5-HT5 receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225172A (en) * 1983-06-03 1984-12-18 Yamanouchi Pharmaceut Co Ltd Novel guanidinothiazole derivative and its preparation

Also Published As

Publication number Publication date
MA26540A1 (en) 2004-12-20
ZA988064B (en) 1999-05-28
WO1999011637A1 (en) 1999-03-11
EP1015438A1 (en) 2000-07-05
SA98190653A (en) 2005-12-03
CO4970736A1 (en) 2000-11-07
CA2302361A1 (en) 1999-03-11
JP2001514257A (en) 2001-09-11
EP1015438A4 (en) 2000-11-08
AU9300298A (en) 1999-03-22

Similar Documents

Publication Publication Date Title
PE115699A1 (en) PROTEASE CO-INHIBITORS
PE97999A1 (en) DERIVATIVES OF 4-BROMINE OR 4-IODINE PHENYLAMINE ACID BENZHIDROXAMICO
PE20110588A1 (en) BENZOTHIAZOLE DERIVATIVES AS ANTI-CANCER AGENTS
CY1115684T1 (en) Fungicidal Mixtures Containing Substituted Anilides 1-Methylsopyrazole-4-Hydroxyacetic Acid
PE20020858A1 (en) INDANIL ACILLATED AMINES
CO4970728A1 (en) 2-AMINOPYRIDINES CONTAINING CONDENSED RING SUBSTITUTES
ES2100727T3 (en) CELLULOSE CONTAINED MOLDING OR YARN MATTER.
DK0613636T3 (en) Toothbrush with a flexibly connected zone between head and shaft
BR0110492A (en) A compound, a pharmaceutical composition comprising such a compound, a process for preparing a pharmaceutical composition, using a compound and a process for preparing a compound.
BR0215517A (en) Antiseptic composition, and methods for disinfecting tissue and for producing an antiseptic composition
DE69710297D1 (en) Polyhalogenalkyletherderivate as well as containing liquid crystal composition and liquid crystal display elements
PE20010118A1 (en) IMIDAZOLE COMPOUNDS SUBSTITUTED AS NEUROPEPTIDE ANTAGONISTS AND
ES2189300T3 (en) NEW 6-AMINOURACILOS MODIFIED WITH NH2 AS STABILIZERS FOR HALOGENED POLYMERS.
PE20040190A1 (en) SUBSTITUTE THIAZOLS AND OXAZOLES THAT MODULATE THE ACTIVITY OF PPAR
NO20080323L (en) Compounds and their salts specific to PPAR receptors and EGF receptors and their use in medicine
CL2022003625A1 (en) Naphthalene isoxazoline compounds to control invertebrate pests (divisional patent for invention no. 2073-2020)
ES2179847T3 (en) BIOCATALITICAL METHODS FOR SYNTHESIS AND IDENTIFICATION OF BIOLOGICALLY ACTIVE COMPOUNDS.
PA8576001A1 (en) "DIFENILAZETIDINONAS REPLACED IN RING, PROCEDURE FOR PREPARATION, MEDICATIONS UNDERSTANDING THESE COMPOUNDS AND THEIR USE".
ES2082434T3 (en) TETRAMETILPIPERIDINE COMPOUNDS FOR USE AS STABILIZERS FOR ORGANIC MATERIALS.
ES2148463T3 (en) DIMEROUS COMPOUNDS OF SULFIDE AND OXIDE OF BISACILFOSFINA.
PE20040558A1 (en) DERIVATIVES OF FLUOROBENZAMIDAS AS SELECTIVE INHIBITORS OF MONOAMINE OXIDASE B
AR050576A1 (en) OXADIAZOLONAS WITH AGONIST ACTIVITY OF PPAR-DELTA. PHARMACEUTICAL COMPOSITIONS.
PE20010486A1 (en) HYDROXAMIC ACID COMPOUNDS USEFUL AS INHIBITORS OF MATRIX METALOPROTEINASE
ES2117243T3 (en) NEW LIQUID PHENOLIC ANTIOXIDANTS.
PE20030978A1 (en) METABOLITES OF (3 - {[4-TERC-BUTYLBENZYL) - (PYRIDIN-3-SULFONYL) -AMINO] -METIL} -PHENOXY) -ACETIC ACID

Legal Events

Date Code Title Description
FC Refusal